A series of defeats by domestic pharmaceuticals in patent challenges
Domestic pharmaceutical companies were defeated from patent suits in series. They were against substance patents of Ezetrol(ezetimibe), Forxiga(dapagliflozin) and Pradaxa(dabigatran etexilate) and a crystalline patent of Suglat(ipragliflozin), but they all went in vain on the last 22nd.
The ind...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
